Company profile
Crinetics Pharmaceuticals, Inc.
Pipeline8 assets
- PaltusotineCRN00808 / PALSONIFY / SST2 / oral nonpeptide SST2 agonist / Endocrinology; oncologyAcromegaly (US)ApprovedapprovedUSAcromegaly (EU)Registrationalunder reviewEUCarcinoid syndrome associated with NETsPhase 3clinicalGlobal
- AtumelnantCRN04894 / MC2R/ACTH receptor / oral nonpeptide ACTH receptor antagonist / EndocrinologyCongenital adrenal hyperplasia (adult)Phase 3clinicalCongenital adrenal hyperplasia (pediatric)Phase 2/3clinicalACTH-dependent Cushing's syndromePhase 2/3planned
- CRN09682CRN09682 / SST2 / nonpeptide drug conjugate; MMAE payload / OncologySST2-expressing NETs and other SST2-expressing solid tumorsPhase 1/2clinical
- PTH AntagonistPTH receptor / oral nonpeptide antagonist / EndocrinologyHyperparathyroidism and other diseases of hypercalcemiaPreclinicalIND-enabling
- TSH AntagonistTSH receptor / oral nonpeptide antagonist / EndocrinologyGraves' disease; thyroid eye diseasePreclinicalIND-enabling
- SST3 AgonistSST3 / oral nonpeptide agonist / NephrologyPolycystic kidney diseasePreclinicalIND-enabling
- Oral GLP-1 NonpeptideGLP-1 receptor / oral nonpeptide agonist / Metabolic diseaseDiabetes; obesityPreclinicaldisclosed
- Oral GIP NonpeptideGIP receptor / oral nonpeptide agonist / Metabolic diseaseDiabetes; obesityPreclinicaldisclosed
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.